We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Wave Bioreactors Added to Macrogenics cGMP Manufacturing Facility

Read time: Less than a minute

Wave Biotech, LLC, has announced that MacroGenics has installed 200-liter Wave Bioreactors® for its new facility.

The Wave Bioreactors® will enable MacroGenics - which is focused on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases - to produce monoclonal antibodies under current Good Manufacturing Practice standards.

"Wave Biotech's disposable cell culture technology is ideal for the MacroGenics application because it is scalable, up to 500 liters," said Vijay Singh, founder & president of Wave Biotech.

"Our large scale bioreactors use proprietary technology which has been tested and refined for the last 5 years, and we can also roll-in a large scale 500 liter production capability bioreactor into an existing facility today, without the requirements of piping or steam," added Singh, whom is the inventor of the Wave Bioreactor®.

Further he said, "There is no waiting period. All that is needed is to plug and play."

MacroGenics officially opened their new manufacturing facility on October 19th.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.